Coronado Biosciences (CNDO) is zero revenue biotech with two immunotherapy candidates in clinical development. Trichuris suis ova [TSO] or CNDO-201 are the eggs of a parasitic worm that naturally infect pigs, and to a far lesser extent people. CNDO-109 is a biologic that activates the immune system's natural killer cells.
TSO is in varying stages of development for 8 separate indications, of which Chron's disease is most advanced. Although CNDO-109 may have an effect on a variety of cancers, it is currently in Phase 1/2 trials for acute myeloid leukemia, and preclinical stages for Multiple Myeloma.
When good hygiene goes bad
Autoimmune diseases like Crohn's are on the rise nearly everywhere in the developed world. A popular explanation for the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|